Table 1 Clinical characteristics and outcomes of H1N1(v) critically ill immunocompromised patients
From: Clinical features of H1N1 2009 infection in critically ill immunocompromised patients
Patient | Type of immune deficiency | Chemotherapy | Immuno- suppressive agents | Lymphocyte count | Time, in days, from respiratory symptoms to ICU admission | Ventilatory support | Superinfection | Anti-infectious agentsa | Outcome |
|---|---|---|---|---|---|---|---|---|---|
1 | Chronic myeloid leukemia | No | No | 4,000 | 3 | NIV | Clinically documented | C3G/macrolide | Alive |
2 | Allogeneic BMT (12 months ago) with GVHD | No | Yes (steroid/CIs) | 800 | 1 | MV | Clinically documented | Piperacillin/FQ | Dead |
3 | Allogeneic BMT (15 months ago) with GVHD | No | Yes (steroid/CIs) | 600 | 1 | NIV | Escherichia coli + Aspergillus fumigatus | Imipeneme/FQ | Dead |
4 | Autologous BMT for multiple myeloma | Yes | Yes (steroid) | 50 | 5 | None | Clinically documented | Piperacillin/macrolide | Alive |
5 | Renal transplantation | Yes | Yes (steroid/CIs/MMF) | 1,200 | 5 | MV | Pseudomonas aeruginosa | Piperacillin/macrolides | Dead |
6 | HIV | No | No | 1,800 | 3 | None | Streptococcus pneumoniae | C3G/macrolide | Alive |
7 | Autologous BMT for multiple myeloma | Yes | Yes (steroid) | 100 | 5 | MV | Clinically documented | Piperacillin/macrolide | Alive |
8 | Myelodysplasia | Yes | Yes (steroid) | 2,000 | 3 | MV | E. coli | Piperacillin/macrolide | Dead |
9 | Mantle cell lymphoma | No | No | 100 | 2 | NIV and MV | S. pneumoniae | C3G/macrolide | Alive |
10 | Solid organ transplantation | No | Yes (steroid) | 2,000 | 2 | None | S. pneumoniae | C3G/macrolide | Alive |